|
Atticus Pharma, an SC Launch, Inc. portfolio company, announced positive first-in-human clinical data for ATC-002, its topical treatment candidate for androgenic alopecia, demonstrating significant new hair growth and strong safety and tolerability in a 6-month, randomized, placebo-controlled study. Powered by its proprietary Z-pod® sustained-release technology, ATC-002 showed continued hair growth improvements through six months—supporting advancement toward a potential Rx treatment for the 80 million Americans affected by hair loss. Read more.
|